CDC6 is a possible biomarker for hepatocellular carcinoma
1Department of Hepatobiliary and Pancreatic Surgery, The Secondary Hospital of Tianjin Medical University No. 23 Pingjiang Road, Hexi District, Tianjin 300211, China.
International Journal of Clinical and Experimental Pathology
|August 9, 2021
Summary
The expression of CDC6 is elevated in hepatocellular carcinoma and linked to tumor progression. This finding suggests CDC6 may serve as a valuable biomarker for liver cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Hepatology
Background:
- Cell division cycle 6 (CDC6) is implicated in tumorigenesis across various cancers.
- The specific role of CDC6 in hepatocellular carcinoma (HCC) progression requires further elucidation.
Purpose of the Study:
- To investigate the expression levels and clinical significance of CDC6 in hepatocellular carcinoma.
- To determine if CDC6 can serve as a potential biomarker for HCC.
Main Methods:
- Utilized the GEPIA database to assess CDC6 expression across multiple cancer types.
- Compared CDC6 expression in HCC tissues versus normal liver tissues using immunohistochemical staining.
- Performed statistical analyses, including t-tests and chi-squared tests, to evaluate CDC6's role in HCC.
Main Results:
- CDC6 expression was significantly upregulated in malignant carcinoid, melanoma, urothelial carcinoma, and notably, hepatocellular carcinoma.
- Elevated CDC6 levels correlated with clinical progression in HCC, specifically with increased tumor size and number of tumor nodes.
- No significant correlation was found between CDC6 expression and patient age, gender, or alpha-fetoprotein (AFP) levels.
Conclusions:
- CDC6 expression is closely associated with clinical characteristics in hepatocellular carcinoma.
- CDC6 emerges as a potential novel biomarker for the diagnosis and prognosis of HCC.
